Biomarker Concordance of Invasive Breast Carcinoma on Re-Evaluation: A Comprehensive Retrospective Real-World Analysis of Paired Samples
Biomarker re-evaluation is not mandatory between CNB and upfront resection or evaluating HER2 status alone, but one in five patients may show discordance at metastasis/recurrence. We recommend re-evaluation in recurrent/metastatic settings, post-treatment, >6 months' time interval, or poorly fixed material, which is of particular relevance in LMICs.
Authors
- Sangeeta Desai (ORCID: https://orcid.org/0000-0002-3588-9888)
- Palak Popat (ORCID: https://orcid.org/0000-0002-6495-0721)
- Sudeep Gupta (ORCID: https://orcid.org/0000-0002-6742-6378)
- Shalaka Prakash Joshi (ORCID: https://orcid.org/0000-0003-3813-4680)
- Tanuja M. Shet (ORCID: https://orcid.org/0000-0001-9294-9704)
- Asawari J. Patil (ORCID: https://orcid.org/0000-0002-8203-986X)
- Tabassum Wadasadawala (ORCID: https://orcid.org/0000-0003-2167-420X)
- Ayushi Sahay (ORCID: https://orcid.org/0000-0003-3574-8855)
- Archita Juneja
- Pooja Padwale
Institutions
- Homi Bhabha National Institute (IN)
- Tata Memorial Hospital (IN)
Publication Details
- Journal
- JCO Global Oncology
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1200/go-25-00358
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00